Thermodynamic, spectral and antimicrobial activity of inclusion complexes of acridone and its oxime with β-cyclodextrin

Authors

1 PG Department of Chemistry, Berhampur University, Bhanja Vihar 760007, India

2 S.B.R. Govt. Women’s (Auto) College, Berhampur 760001, India

Abstract

One of the methods to enhance bio-accessibility of drugs like Acridone and its oxime is to
form inclusion complexes with β-cyclodextrin. The formation of such complexes has been
confirmed by changes in spectral characteristics and melting point data. The aqueous phase
solubility studies reveal 1:1 stoichiometry between the compound and, β-cyclodextrin. The study
of thermodynamic parameters like ΔG, ΔH, ΔS indicates the inclusion complex formation to be
exothermic and spontaneous. The study of antimicrobial activity of these compounds indicates
that the microbes like E. coli and P. aeruginosa are susceptible and the susceptibility increases
significantly after formation of inclusion complex.

Keywords


[1] P. Belmont, I. Dorange, Expert opinion on Therapeutic Patents 18 (2008) 1211-1215.
[2] P. Belmont, J. Bosson , T. Godet, M. Tiano, Curr. Med. Chem. Anticancer Agents 7 (2007) 139-144.
[3] A. Verloop, W. Hoogentraten, J. Tipker, Drug Design 7 (1976) 165-168.
[4] B. Pose-Vilarnovo, I. Perdomo-Lopez, M. Echezarreta-Lopez, Eur. J. Pharm. Sci. 13 (2001) 325-334.
[5] V.G. Belikov, E.V. Kompantseva, Khim-Farm Zh. 24 (1990) 19-27.
[6] H. Yano, F. Hirayama, H.Arima , J. Pharm. Sci. 90 (2001) 493-496.
[7] X. Jane, M. Kelly, Antimicrob. Agents Chemother. 51 (2007) 4133-4137.
S.S. Nayak & S. Panda / J. Iran. Chem. Res. 2 (2009) 257-265
265
[8] T. Higuchi, K.A. Connors Adv. Anal. Chem. Instrum. 4 (1965) 117-211.
[90] C.F.H. Allen, G.H.W. Mckee, Organic Syntheses Coll. 2 (1943) 15-16.
[10] N. Shufang, F. Xiawen, P. Ying, Y. Xingang, W. Chow, P. Weisan, P. Arch, Pharm. Res. 30 (2007)
991-993
[11] S. Panda, J.K. Tripathy, J. Env. Res. Dev. 3 (2008) 45-49.
[12] M.J. Pelzar, E.C.S. Chan, N.R. Kreig, Microbiology, Wiley Interscience, New York, 1983.
[13] K.J. Ryan, C.G. Ray, Sherris Medical Microbiology, McGraw Hill ,London, 2004.
[14] K.G. Mohamed, C.A. Moji , Pharm. Dev. Tech. 6 (2001) 315-318.
[15] O. Chen, D. Guowang, Chem. J. Internet. 6 (2004) 37-39.
[16] A. Modi, P. Tayade, Indian J. Pharm. Sci. 69 (2007) 274-278.
[17] H.A. Benesi, J.H. Hilderbrand, J. Am. Chem. Soc.71 (1999) 2703-2704.
[18] Z. Szetli, Controlled Drug Bioavailability, Wiley Interscience, New York, 1985.
[29] S. Tommasini, D. Raneri, R. Ficarra, M.L. Calabro, R. Stancanelli, J. Pharm. Biomed. Anal. 35
(2004) 379-382.
[20] R.A. Rajewski, V.J. Stella, J. Pharm. Sci. 85 (1996) 1142-1145.
[21] Y.L. Loukas, V. Vraka, G. Gregoridias, J. Pharm. Biomed. Anal. 16 (1997) 263-271.
[22] T. Stalin, P.V. Rani, B. Shanthi, A. Sekar, N. Rajendiran, Indian J. Chem. Sect A 45 (2006) 1113-
1120.
[23] A.V. Astakhova, N.B. Demina, Pharm. Chem. J. 38 (2004) 105-108.